Supernus Pharmaceuticals Inc (SUPN)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total current assets	US$ in thousands	686,070	640,003	591,002	544,321	493,113	449,360	423,538	883,340	734,151	663,886	625,120	568,516	601,590	668,375	639,244	586,023	630,417	552,015	557,153	557,048
Total current liabilities	US$ in thousands	292,397	291,508	308,656	314,554	290,196	287,534	252,590	731,545	687,958	725,987	735,536	284,558	315,379	234,711	283,447	240,812	245,108	299,606	269,276	168,335
Current ratio		2.35	2.20	1.91	1.73	1.70	1.56	1.68	1.21	1.07	0.91	0.85	2.00	1.91	2.85	2.26	2.43	2.57	1.84	2.07	3.31

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $686,070K ÷ $292,397K
= 2.35

The current ratio of Supernus Pharmaceuticals Inc has fluctuated over the years, indicating changes in the company's short-term liquidity position. The ratio, which measures the company's ability to meet its short-term obligations with its current assets, was relatively high at the end of March 2020, standing at 3.31. This indicates the company had significant current assets compared to current liabilities at that point in time.

However, the current ratio decreased in the following quarters, dropping to 0.85 by June 30, 2022. This sharp decline could indicate potential liquidity concerns or challenges in managing short-term obligations. It is important for investors and stakeholders to further investigate the reasons behind this significant decrease in the current ratio.

Subsequently, the current ratio improved gradually over the next few quarters, reaching 2.35 by the end of December 31, 2024. This uptrend suggests that Supernus Pharmaceuticals Inc managed to strengthen its short-term liquidity position and increase its current assets relative to current liabilities.

Overall, the current ratio trend of Supernus Pharmaceuticals Inc reflects fluctuations in its short-term liquidity position over the analyzed period. Investors and stakeholders should continue to monitor the company's current ratio along with other financial metrics to assess its overall financial health and ability to meet its short-term obligations.